EOLS
Evolus, Inc.
$6.09
-0.36
(-5.58%)
Mkt Cap
401.06M
Volume
611,119
52W Range
3.86-10.62
Sector
Healthcare
Beta
1.29
EPS (TTM)
-0.67
P/E Ratio
-8.30
Revenue (TTM)
301.79M
Rev Growth (5Y)
+39.4%
EPS Growth (5Y)
N/A
Company Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.18M | 266.27M | 202.09M | 148.62M | 99.67M | 56.54M | 34.92M | 0 | 0 | 0 | 0 |
| Net Income | (51.64M) | (50.42M) | (61.69M) | (74.41M) | (46.81M) | (163.01M) | (90.03M) | (46.87M) | (4.48M) | (20.07M) | (31.11M) |
| EPS | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Free Cash Flow | (45.71M) | (19.47M) | (35.63M) | (87.85M) | (34.36M) | (61.01M) | (97.95M) | (25.68M) | (13.04M) | (13.27M) | N/A |
| FCF / Share | -0.71 | -0.31 | -0.63 | -1.57 | -0.69 | -1.81 | -3.47 | -1.05 | -0.55 | -0.71 | N/A |
| Operating CF | (42.27M) | (18.00M) | (34.01M) | (84.91M) | (33.39M) | (57.87M) | (93.38M) | (25.67M) | (13.04M) | (13.27M) | N/A |
| Total Assets | 225.87M | 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | 240.44M | 171.84M | 152.23M | 77.50M | N/A |
| Total Debt | 155.00M | 129.98M | 126.55M | 74.42M | 74.74M | 138.32M | 96.55M | 16.90M | 211.33M | 59.76M | N/A |
| Cash & Equiv | 53.83M | 86.95M | 62.84M | 53.92M | 146.26M | 102.56M | 109.89M | 93.16M | 0 | 0 | N/A |
| Book Value | (23.11M) | 5.52M | (20.69M) | 18.50M | 81.88M | (72.96M) | 79.46M | (123.03M) | (75.54M) | (7.11M) | N/A |
| Return on Equity | N/A | -9.13 | N/A | -4.02 | -0.57 | N/A | -1.13 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.14M | 90.30M | 68.97M | 69.39M | 68.52M | 78.95M | 61.09M | 66.91M | 59.33M | 61.00M | 50.02M | 49.35M |
| Net Income | (10.67M) | 130,000 | (15.74M) | (17.14M) | (18.89M) | (6.79M) | (19.17M) | (11.35M) | (13.11M) | (11.83M) | (16.92M) | (18.14M) |
| EPS | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 | -0.11 | -0.30 | -0.18 | -0.22 | -0.21 | -0.30 | -0.32 |
| Free Cash Flow | (10.37M) | 11.35M | (16.83M) | (25.48M) | (17.49M) | 3.45M | (7.13M) | (7.72M) | (11.41M) | 452,000 | (1.46M) | (13.32M) |
| FCF / Share | -0.16 | 0.18 | -0.26 | -0.39 | -0.27 | 0.06 | -0.11 | -0.12 | -0.19 | 0.01 | -0.03 | -0.23 |
| Operating CF | (9.95M) | 12.83M | (14.67M) | (24.79M) | (15.63M) | 4.81M | (5.72M) | (6.47M) | (10.62M) | 813,000 | (924,000) | (13.31M) |
| Total Assets | 220.65M | 225.87M | 219.00M | 228.80M | 213.36M | 232.57M | 229.61M | 233.77M | 226.18M | 189.00M | 167.97M | 168.98M |
| Total Debt | 164.90M | 155.00M | 154.89M | 154.91M | 130.20M | 129.98M | 8.67M | 126.75M | 126.65M | 126.55M | 101.44M | 96.82M |
| Cash & Equiv | 49.79M | 53.83M | 43.52M | 61.74M | 67.89M | 86.95M | 85.03M | 93.67M | 96.96M | 62.84M | 38.69M | 41.70M |
| Book Value | (28.78M) | (23.11M) | (28.76M) | (18.65M) | (6.60M) | 5.52M | 5.89M | 19.31M | 18.44M | (20.69M) | (19.37M) | (6.96M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -1.23 | -3.25 | -0.59 | -0.71 | N/A | N/A | N/A |
EOLS News
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus to Report First Quarter Financial Results on May 4, 2026
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock